The selection of China’s top 50 most valuable investment enterprises was initiated by Zero2IPO Group.It is the first annual selection event focusing on high-growth enterprises in the investment community.Since its launch in 2006,it has been successfully held for ten years,which is hailed as an "industrial investment vane".

On December 2,2015,at the Sixth China’s High-Growth Enterprise CEO Summit,the list of 10th “China's top 50 most valuable investment enterprises” was officially released.Different from the previous sessions,for the first time,the list of “China's top 50 most valuable investment enterprises” of this session divides list of enterprises into "Sprout List" and "Influential List" according to the different development stages and scales of enterprises."Suzhou Kintor" was honored to be included in the list of 10th anniversary of China's Top 50 Most Valuable Enterprises to Invest in 2015.

About Zero2IPO Group

Founded in 1999,Zero2IPO Group is a China's leading integrated service and investment institution in the field of private equity investment.Its subordinate businesses includes: Zero2IPO Research Center,Zero2IPO Media,Zero2IPO Capital,Zero2IPO Wealth,Zero2IPO Venture Capital,Zero2IPO Investment,mainly covering research consulting,data products,information,conference forums,investment banking services,direct investment,mother fund management,and wealth management.After 15 years of development,Zero2IPO Group has now become China's premier integrated service platform for equity investment.

Bear Responsibilities,Bear Loneliness

On July 15,2015,"Suzhou Kintor Pharmaceuticals,Inc.("Suzhou Kintor") announced that it has received a USD10 million investment from Highlight Medical focused on health industry.Established in 2009,Suzhou Kintor is a high-tech innovative enterprise dedicated to the research and development of new anti-cancer drugs.Prior to this,the company received early investment from institutions such as bioVenture.

Dr.Dr.Tong,the founder and president of Suzhou Kintor,holds a bachelor's degree and a master's degree in chemistry from Peking University,and received Ph.D.in pharmacology from Memorial Sloan-Kettering Cancer Center of Cornell University.Dr.Tong has extensive experiences in the fields of drug discovery,tumor biology and tumor animal models.In 2012,he won the title of 3rd Overseas High-Level Leading Talent of the Park.

"I think every returnee who returns to start a business is eager to realize his or her ideals,ambitions,and values in life.Our generation particularly has responsibility and dream of doing something for the country.To return to China and struggle means to give up the foundation already built in the United States.It takes a lot of courage to start from scratch."

Dr.Tong resigned and returned to China in 2008.At that time,an accidental opportunity get him into contact with domestic pharmaceutical enterprises.He was shocked and touched when he saw that domestic enterprises had caught up with the United States in terms of hardware but lacked independent research and development projects.He had a short discussion on cooperative establishment of a novel drugs research and development company with domestic pharmaceutical enterprises,but the idea failed.This unsuccessful incident,however,gave Dr.Tong an opportunity to gain certain understanding of how to localize and start a business in China.Hence,in 2009,he founded Suzhou Kintor in Suzhou BioBay."At that time,financing was difficult during the spreading financial crisis.Therefore,Suzhou Kintor went through a difficult start-up period.Fortunately,it receives the park's loans and financing support and thus runs to date."

The management and research team of Suzhou Kintor is made up by experts with doctorate degrees from well-known universities in the United States.They have years of experiences in management,R&D and technology services in pharmaceutical enterprises in the United States.With complementary knowledge structures,they have a good record of cooperation,and are fully capable of dealing with challenges,risks and pressure.Suzhou Kintor is a rare high-tech innovative enterprise in China led by two “Thousand Talents Program” experts.

Research and development of novel drugs is a prolonged process,often taking more than ten years,and failed cases are in the majority.Dr.Tong said that Suzhou Kintor has cultivated a young scientific research team."They have enthusiasm for novel drugs projects and have the ability to learn and innovate.At the same time,they undertake different R&D projects and often conduct interdisciplinary discussions."

Now,governments at all levels attach great importance to novel drugs development.The State,Jiangsu Province,and Suzhou City have all offered special investment fund,and the Park also provides considerable matching funds.This is especially important for science-and-technology enterprises like us that are devoted to novel drugs research and development without any profit.The government's capital support has also greatly driven venture capital's attention to early and mid-term novel drugs development projects.

Dr.Tong has his own understanding about the novel drugs research and development environment: "Now our novel drugs research and development enterprises and entrepreneurs should actively seek support from the government and entrepreneurial funds,and at the same time we should be able to bear the loneliness in long-term research and development,make good use of funds and talents and select appropriate projects to develop novel drugs in line with China's international status,so that we can attract more national and private capital support for novel drugs and create a good entrepreneurial environment for future returnees engaged in novel drugs development."

At present,Suzhou Kintor strives to complete the pre-clinical research and development of new anti-cancer drugs as soon as possible,so that human clinical trial approvals in China can be obtained within one to two years to form a supply chain of pre-clinical research and development,clinical trials and final product for targeted anti-cancer drugs,thereby increasing the company's overall competitiveness and value,and achieving the goal of becoming an internationally competitive pharmaceutical company.